• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2018 Fiscal Year Final Research Report

Oncolytic virus therapy with HSV-1 for hematological malignancies

Research Project

  • PDF
Project/Area Number 15K09501
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Hematology
Research InstitutionKagawa University

Principal Investigator

Kadowaki Norimitsu  香川大学, 医学部, 教授 (60324620)

Project Period (FY) 2015-04-01 – 2019-03-31
Keywords造血器腫瘍 / ウイルス療法 / 免疫療法
Outline of Final Research Achievements

A recombinant HSV-1, T-01, killed 16 out of 21 human cell lines of hematological malignancies. Positive correlations were observed among the expression levels of HSV-1 receptor nectin-1, entry of T-01, and cytotoxicity. In accord with it, knockdown of nectin-1 decreased entry of T-01, and forced expression of nectin-1 induced cytotoxic activity.
These data indicate that viral entry via nectin-1 is a determining factor of cytotoxicity by oncolytic HSV-1 against hematological malignancies, and that the expression of nectin-1 is a biomarker of the susceptibility of hematological malignancies to HSV-1.

Free Research Field

血液学、免疫学

Academic Significance and Societal Importance of the Research Achievements

がんウイルス療法がさまざまな固形がんに対する免疫療法の1つとして発展しつつあり、中でもHSV-1がメラノーマに対して実用化されている中、このウイルスが造血器腫瘍に対しても有効性が期待できることが示された。このことは、造血器腫瘍に対する免疫療法の選択肢を増やし治療成績の向上につながるとともに、今後ウイルス療法と免疫チェックポイント阻害療法の併用といった複合的免疫療法の開発に発展しうる成果である。

URL: 

Published: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi